한국어
미제공
사전 컨퍼런스 데이
English
한국어
미제공
Explore the Agenda
일정 확인하기
Workshop A 워크숍 A
9:00 am Crossing Important Development Milestones to De-Risk Your TPD Candidates & Enable Global Industry-Standard Compliant Drug Profiles For Your Degraders
As Korean biotechs advance from discovery toward clinical development, the transition often exposes critical gaps in technical standards and strategic planning. This workshop will provide actionable guidance on implementing global best practices for assay design, selectivity profiling, and translational alignment, while addressing the unique challenges faced by emerging TPD companies in Asia. Attendees will gain clarity on what global partners expect, how to structure industry standard compliant data packages, and how to better transition into the clinic.
Key Takeaways:
- Exploring the PLK1 bifunctional degrader for the treatment of SCLC and other cancer types
- Discovering the potent PROTACS and degrader antibody conjugates for “undruggable” targets including KRAS G12D, colorectal and pancreatic cancers
- The discovery of clinical-stage BTK degrader, BGB-16673 and overcoming on-target resistance from BTK inhibitors
11:30 am Workshop A Ends
Your opportunity to attend the talks in the other events part of the World Targeted Therapeutics Summit South Korea by Hanson Wade
12:30 pm Lunch
Workshop B 워크숍 B
1:30 pm Integrating Novel Platforms & AI Technologies Into Your Workflows to Improve Target Validation, Accelerate Discovery & Enable Scalable Molecular Glue Development
This workshop will help attendees master critical enabling technologies to accelerate TPD drug discovery. Discussions will revolve around how to design and apply workflows for selectivity profiling and mechanistic clarity, and how to use AI-driven analytics to interpret complex datasets and accelerate degrader design and modeling. By the end of the session, attendees will have practical strategies to improve reliable data generation and analysis and how to use this to inform critical drug design decisions.
Key Takeaways:
- Integrating high-throughput discovery platforms into your workflows to accelerate the discovery and development of molecular glues
- Beyond screening: Accelerating TPD and induced proximity discovery with agentic AI and large language models
- Exploring case studies on how advanced biotechs combine the latest platform technology and AI tools to reduce experimental burden, improve translational predictability, and enable scalable discovery
- Why early proteomics matters in TPD drug discovery